News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Application based on results from the TROPION-Breast01 Phase III trial
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Combination shows consistent benefit across prespecified post-progression outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Subscribe To Our Newsletter & Stay Updated
